MedTrace Logo

Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis

NCT01712360 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2016-07-14

Study results available
· View outcomes & findings →

Summary

This study is being done to see how the body is affected when a study drug is applied to both feet if the subject has athlete's foot or to both feet and the groin area if the subject has both athlete's foot and jock itch. Safety of the drug and how well the drug works will also be measured.

Conditions

  • Tinea Pedis
  • Tinea Cruris

Interventions

DRUG

NAFT500 (pediatric)

Applied to both feet and groin area

DRUG

NAFT600 (pediatric)

Applied to both feet only

DRUG

NAFT500 (adult)

Applied to both feet and groin area

DRUG

NAFT600 (adult)

Applied to both feet

Sponsors & Collaborators

  • Merz North America, Inc.

    lead INDUSTRY

Principal Investigators

  • Alan Fleischer, MD · Merz Pharmaceutical, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States
  • Dominican Republic
  • Honduras

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01712360 on ClinicalTrials.gov